# EDGAR Filing Document

**Accession Number:** 0001166272
**File Stem:** 0001493152-23-002258
**Filing Date:** 2023-1
**Character Count:** 8126
**Document Hash:** e686cd0d7ed7a46949044cf48e3dc5c7
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001493152-23-002258.hdr.sgml**: 20230124

**ACCESSION NUMBER**: 0001493152-23-002258

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 3

**CONFORMED PERIOD OF REPORT**: 20230124

**FILED AS OF DATE**: 20230124

**DATE AS OF CHANGE**: 20230124

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** GENETIC TECHNOLOGIES LTD
- **CENTRAL INDEX KEY:** 0001166272
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **IRS NUMBER:** 000000000

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-51504
- **FILM NUMBER:** 23545802

**BUSINESS ADDRESS:**
- **STREET 1:** 60-66 HANOVER STREET
- **CITY:** FITZROY, VICTORIA
- **STATE:** C3
- **ZIP:** 3065
- **BUSINESS PHONE:** 011613-9415-1135

**MAIL ADDRESS:**
- **STREET 1:** 60-66 HANOVER STREET
- **CITY:** FITZROY, VICTORIA
- **STATE:** C3
- **ZIP:** 3065

**FORM 6-K**

**U.S. SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**REPORT OF FOREIGN PRIVATE ISSUER**

**PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE**

**SECURITIES EXCHANGE ACT OF 1934**

**dated January 24, 2023**

**Commission File Number 0-51504**

**GENETIC TECHNOLOGIES LIMITED**

(Exact Name as Specified in its Charter)

**N/A**

(Translation of Registrant's Name)

**60-66 Hanover Street**

**Fitzroy**

**Victoria 3065 Australia**

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes ☐ No ☒

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): Not applicable.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused the Report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: January 24, 2023

---

| | |
|:---|:---|
| GENETIC TECHNOLOGIES LIMITED | GENETIC TECHNOLOGIES LIMITED |
| By: | */s/ Tony Di Pietro* |
| Name: | Tony Di Pietro |
| Title: | Company Secretary |

---

EXHIBIT INDEX

---

| | |
|:---|:---|
| **Exhibit** | **Description of Exhibit** |
| 99.59 | [20230124 – ASCOGI Presentation FINAL](ex99-59.htm) |

---

## Exhibit 99.59

**Exhibit 99.59**

---

| | |
|:---|:---|
| ASX Market Announcement | ![](ex99-59_001.jpg) |

---

**Improved Clinical Colorectal Cancer Risk Prediction Model Integrating Polygenic Risk Presented at ASCOGI Cancer Symposium**

**Melbourne, Australia, 24 January 2023:** Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, "Company", "GTG") – a global leader in genomics-based tests in health, wellness and serious disease – is pleased to announce a poster presentation by Dr Erika Speath at the prestigious American Society of Clinical Oncology Gastroenterology Cancer Symposium in San Francisco last weekend. The Poster titled "***Improvement of a clinical colorectal cancer risk prediction model integrating polygenic risk"*** was authored by GTG's Science Team including Erika Spaeth, Aviv Gafni, Richard Allman and Gillian Dite.

**Highlights:**

● The
 poster demonstrates improved performance, identifying patients at risk of developing colorectal
 cancer by expanding number of SNPs from 45 to 144

● The
 patients in the top risk category showed a 27% improvement compared with the 45 SNP geneType
 model

● The
 improved performance was consistent across multiple genetic ancestries, greatly improving
 the utility of the test leading to increased surveillance in high risk patients.

● The
 poster builds on an earlier publication by GTG that validated the geneType model, focusing
 on its' ability to stratify patients at higher risk of developing one of the world's
 most common cancers

The poster demonstrated a significant improvement in predicting a patient's risk of developing colorectal cancer by expanding the number of genetic markers, commonly called Single Nucleotide Polymorphisms (SNPs) used as an important element of GTG's geneType Risk Assessment Test for colorectal cancer

Colorectal cancer risk stratification can be crucial to improving screening and risk-reducing recommendations, and consequently does better than a one-size-fits-all screening regimen. Current screening guidelines in the UK, USA and Australia focus solely on family history and age for risk prediction. Unfortunately, the vast majority of the population do not have any hereditary or familial history and would remain unaware that they could be at elevated risk of developing colorectal cancer. GTG's geneType Risk Assessment test is directly targeting this population to enable the early identification of colorectal cancer.

An earlier publication in 2021 by GTG's science team titled "***Ability of known colorectal cancer susceptibility SNPs to predict colorectal cancer risk: A cohort study within the UK Biobank"*** was an important validation of the geneType Risk Assessment test. The test uses 45 SNPs combined with family history offering a significant improvement in risk stratification particularly with the potential to be used in broad based population screening.

GTG's Director of Clinical and Scientific Affairs, Dr Erika Spaeth noted "By expanding the panel of SNPs in our polygenic risk from 45 to 144 we are able to show a significant improvement in identifying patients in the top risk category. GTG is committed to continuous product improvement with the goal of positively impacting a patient's screening and risk-reduction opportunities".

Simon Morriss added "The health economics demonstrated by our geneType breast cancer risk assessment test Budget Impact Model provide a pathway to reimbursement for the company's enhanced risk assessment test for colorectal cancer. The team at GTG continue to build a strong, relevant portfolio of risk assessment tests that enable patients, or those individuals with an increased risk of developing disease, navigate treatment options, implement disease prevention strategies and make lifestyle changes to reduce the risk of disease development."

---

| | |
|:---|:---|
| Genetic Technologies Limited | 60-66 Hanover Street |
| <u>www.genetype.com</u> | Fitzroy Victoria 3065 |
| <u>info@gtglabs.com</u> | Australia |
| ABN 17 009 212 328 | +61 3 8412 7000 |

---

![](ex99-59_001.jpg)

-END-

Authorised for release by the board of directors of Genetic Technologies Limited.

**Enquiries**

**Investor Relations**

Adrian Mulcahy

Automic Markets

M: +61 438 630 411

E: <u>adrian.mulcahy@automicgroup.com.au</u>

**About Genetic Technologies Limited**

Genetic Technologies Limited (ASX: GTG; Nasdaq: GENE) is a diversified molecular diagnostics company. A global leader in genomics-based tests in health, wellness and serious disease through its geneType and EasyDNA brands. GTG offers cancer predictive testing and assessment tools to help physicians to improve health outcomes for people around the world. The company has a proprietary risk stratification platform that has been developed over the past decade and integrates clinical and genetic risk to deliver actionable outcomes to physicians and individuals. Leading the world in risk prediction in oncology, cardiovascular and metabolic diseases, Genetic Technologies continues to develop risk assessment products. For more information, please visit <u>www.genetype.com</u>

---

| | |
|:---|:---|
| Genetic Technologies Limited | 60-66 Hanover Street |
| <u>www.genetype.com</u> | Fitzroy Victoria 3065 |
| <u>info@gtglabs.com</u> | Australia |
| ABN 17 009 212 328 | +61 3 8412 7000 |

---